NSE
Caplin Point Laboratories LimitedCAPLIPOINT
Caplin Point Laboratories Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products. It focuses on producing high-quality medicines for various therapeutic areas.
| Key products | Pharmaceuticals, Vaccines |
|---|---|
| Geography | India, Middle East, Africa |
| Competitors | Dr. Reddy's Laboratories Limited, Cipla Limited |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Interim Dividend - Rs 4 Per Share
ex 2026-05-29
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ACUTAAS | +₹98.2 Cr | 1 | — | — | +4 | 6 |
| 2 | CAPLIPOINTThis | — | — | — | — | — | — |
| 3 | ACMESOLAR | — | — | — | — | +3 | 6 |
| 4 | AADHARHFC | — | — | — | — | — | — |
| 5 | AARTIIND | — | — | — | — | — | — |
| 6 | ACE | +₹0 Cr | 2 | — | — | — | — |
| 7 | AAVAS | −₹1.9 Cr | 2 | — | — | — | — |
| 8 | ABFRL | −₹142.6 Cr | 4 | — | — | — | — |
| 9 | ABLBL | −₹314.4 Cr | 29 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • [object Object]
- • [object Object]
Opportunities
- • [object Object]
- • [object Object]
Threats
- • [object Object]
- • [object Object]
AI-generated from our data — verify before relying on it.
- 2026-06-16FilingCaplin Point Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) ofShareholding Disclosure
- 2026-05-29ActionInterim Dividend - Rs 4 Per ShareDividend
- 2025-09-12ActionDividend - Rs 3 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 2Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
No bulk/block deals for CAPLIPOINT in this window.
News & chatter on CAPLIPOINT
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.